Sonoma Pharmaceuticals (SNOA) Return on Capital Employed (2011 - 2025)

Sonoma Pharmaceuticals' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 29.05% for Q4 2025.

• In Q4 2025, Return on Capital Employed rose 1570.0% year-over-year to 29.05%; the TTM figure through Dec 2025 stood at 29.05% (up 1570.0% YoY), while the FY2025 annual figure was 36.66%, up 329.0% from the prior year.
• Return on Capital Employed was 29.05% for Q4 2025 at Sonoma Pharmaceuticals, up from 31.5% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 27.52% in Q1 2021 to a low of 61.65% in Q4 2022.
• Historically, Return on Capital Employed has averaged 40.78% across 5 years, with a median of 40.69% in 2023.
• The sharpest annual moves came in 2021 and 2022: Return on Capital Employed soared 4091 bps in 2021, then tumbled 2575 bps in 2022.
• A 5-year view of Return on Capital Employed shows it stood at 35.89% in 2021, then slumped by 72 bps to 61.65% in 2022, then surged by 35 bps to 40.16% in 2023, then retreated by 11 bps to 44.75% in 2024, then jumped by 35 bps to 29.05% in 2025.
• The last three Return on Capital Employed figures came in at 29.05% (Q4 2025), 31.5% (Q3 2025), and 39.07% (Q2 2025), per Business Quant data.